The company used two real-world data sets from Israel, both of which showed evidence that an additional booster increases immunogenicity and lowers rates of confirmed infections and severe illness, according to the release.
Pfizer also said “emerging evidence” suggests effectiveness against both symptomatic COVID-19 and severe infection wanes three to six months after initial booster dosage.
“These early studies indicate that an additional booster dose of the Pfizer-BioNTech COVID-19 vaccine administered at least four months after an initial booster dose could restore antibody titers to peak post-third dose titer levels, improve protection against both infection and severe disease in individuals 60 years of age and older in Israel, and have a similar safety profile to that of previous doses,” the news release said.
Editor’s note: This piece was updated March 16 to reflect a news release from Pfizer.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
